Whiting Petroleum Corporation (WLL) saw its value decrease by -1.07% as the stock dropped $-0.13 to finish the day at a closing price of $12.04. The stock was lighter in trading and has fluctuated between $3.35-$14.44 per share for the past year. The shares, which traded within a range of $11.92 to $12.31 during the day, are up by 42.65% in the past three months and up by 38.23% over the past six months. It is currently trading -2.94% below its 20 day moving average and 8.11% above its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $13.96 a share over the next twelve months. The current relative strength index (RSI) reading is 51.39.The technical indicator lead us to believe there will be no major movement any time soon, hold.
Whiting Petroleum Corporation, an independent oil and gas company, engages in the acquisition, exploration, development, and production of crude oil, natural gas liquids, and natural gas in the Rocky Mountains and Permian Basin regions of the United States. It sells oil and gas to end users, marketers, and other purchasers. As of December 31, 2015, the company had total estimated proved reserves of 820.6 million barrels of oil equivalent; and interests in 3,177 net productive wells on approximately 593,900 net developed acres. Whiting Petroleum Corporation was founded in 1980 and is based in Denver, Colorado.
Ascena Retail Group, Inc. (ASNA) shares were down in last trading by -5.73% to $5.1. It experienced higher than average volume on day. The stock decreased in value by almost -5.73% over the past week and fell -30.23% in the past month. It is currently trading -20.11% below its 50 day moving average and -28.77% below its 200 day moving average. Following the recent decrease in price, the stock’s new closing price represents a -54.71% decrease in value from its one year high of $11.26. The RSI indicator value of 28, lead us to believe that it may correct downwards in the near term.
Ascena Retail Group, Inc., through its subsidiaries, operates as a specialty retailer of apparel, shoes, and accessories for women and tween girls in the United States, Canada, and Puerto Rico. The company operates through six segments: ANN, Justice, Lane Bryant, maurices, dressbarn, and Catherines. It creates, designs, and develops a range of merchandise, including apparel, accessories, footwear, and intimates; lifestyle products comprising cosmetics, bedroom furnishings, and electronics; and wear-to-work, casual sportswear, footwear, and social occasion apparel. The company also offers casual clothing, career wear, dressy apparel, and active wear, as well as special occasion and classic apparel. Its principal brands comprise ANN TAYLOR, LOFT, ANN TAYLOR LOFT, LOU & GREY, JUSTICE, LANE BRYANT, LANE BRYANT OUTLET, CACIQUE, RIGHT FIT, MAURICES, DRESSBARN, CATHERINES, CATHERINES PLUS SIZES, MAGGIE BARNES, LIZ&ME, SERENADA, DRESSBAR, 6th & LANE, and MAURICES IN MOTION. As of July 30, 2016, the company operated approximately 4,900 stores. It also offers its products through its Websites, including anntaylor.com, LOFT.com, louandgrey.com, shopjustice.com, lanebryant.com, cacique.com, maurices.com, dressbarn.com, and catherines.com. The company was formerly known as Dress Barn, Inc. and changed its name to Ascena Retail Group, Inc. in January 2011. Ascena Retail Group, Inc. was founded in 1962 and is based in Mahwah, New Jersey.
Gilead Sciences Inc. (GILD) traded within a range of $71.5 to $72.47 after opening the day at $72.24. The company has seen its stock increase in value by 0.73% so far this year. The stock was up close to 0.31% on active volume in last trading session and closed at $72.13 per share. After the recent gain, the stock is currently holding -28.76% below its 52 week high of $103.1 and 2.49% above its 12-month low of $70.83. The shares are down by over -0.06% in the last three months, and the RSI indicator value of 40.1 is neither bullish nor bearish, tempting investors to stay on the sidelines.
Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The companys products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.